References
- Aleknaviciute J, Tulen JHM, De Rijke YB, et al. The levonorgestrel-releasing intrauterine device potentiates stress reactivity. Psychoneuroendocrinology. 2017;80:39–45.
- Bitzer J. Hormonal contraception and depression: another Pill scandal? Eur J Contracept Reprod Health Care. 2017;22:1–2.
- Lanza di Scalea T, Pearlstein T. Premenstrual dysphoric disorder. Psychiatr Clin North Am. 2017;40:201–216.
- Yonkers KA, Brown C, Pearlstein TB, et al. Efficacy of a new low-dose oral contraceptive with drospirenone in premenstrual dysphoric disorder. Obstet Gynecol. 2005;106:492–501.
- Paterson H, Clifton J, Miller D, et al. Hair loss with use of the levonorgestrel intrauterine device. Contraception. 2007;76:306–309.
- Nilsson CG, Lahteenmaki PL, Luukkainen T. Ovarian function in amenorrheic and menstruating users of a levonorgestrel-releasing intrauterine device. Fertil Steril. 1984;41:52–55.
- Luukkainen T, Lahteenmaki P, Toivonen J. Levonorgestrel-releasing intrauterine device. Ann Med. 1990;22:85–90.
- Andersson K, Odlind V, Rybo G. Levonorgestrel-releasing and copper-releasing (Nova T) IUDs during five years of use: a randomized comparative trial. Contraception. 1994;49:56–72.
- Luukkainen T, Allonen H, Haukkamaa M, et al. Five years’ experience with levonorgestrel-releasing IUDs. Contraception. 1986;33:139–148.
- Sivin I, el Mahgoub S, McCarthy T, et al. Long-term contraception with the levonorgestrel 20 mcg/day (LNg 20) and the copper T 380Ag intrauterine devices: a five-year randomized study. Contraception. 1990;42:361–378.
- Gemzell-Danielsson K, Schellschmidt I, Apter D. A randomized, phase II study describing the efficacy, bleeding profile, and safety of two low-dose levonorgestrel-releasing intrauterine contraceptive systems and Mirena. Fertil Steril. 2012;97:616–622. e1-3.
- Gemzell-Danielsson K, Apter D, Dermout S, et al. Evaluation of a new, low-dose levonorgestrel intrauterine contraceptive system over 5 years of use. Eur J Obstet Gynecol Reprod Biol. 2017;210:22–28.
- Skovlund CW, Kessing LV, Mørch LS, et al. Increase in depression diagnoses and prescribed antidepressants among young girls. A national cohort study 2000–2013. Nord J Psychiatry 2017;71:378–385.
- Brijnath B, Xia T, Turner L, et al. Trends in GP prescribing of psychotropic medications among young patients aged 16–24 years: a case study analysis. BMC Psychiatry. 2017;17:214.
- Lindberg M, Foldemo A, Josefsson A, et al. Differences in prescription rates and odds ratios of antidepressant drugs in relation to individual hormonal contraceptives: a nationwide population-based study with age-specific analyses. Eur J Contracept Reprod Health Care. 2012;17:106–118.
- Keyes KM, Cheslack-Postava K, Westhoff C, et al. Association of hormonal contraceptive use with reduced levels of depressive symptoms: a national study of sexually active women in the United States. Am J Epidemiol. 2013;178:1378–1388.
- Lundin C, Danielsson KG, Bixo M, et al. Combined oral contraceptive use is associated with both improvement and worsening of mood in the different phases of the treatment cycle – a double-blind, placebo-controlled randomized trial. Psychoneuroendocrinology. 2017;76:135–143.
- Pagano HP, Zapata LB, Berry-Bibee EN, et al. Safety of hormonal contraception and intrauterine devices among women with depressive and bipolar disorders: a systematic review. Contraception. 2016;94:641–649.
- Tsai R, Schaffir J. Effect of depot medroxyprogesterone acetate on postpartum depression. Contraception. 2010;82:174–177.
- Civic D, Scholes D, Ichikawa L, et al. Depressive symptoms in users and non-users of depot medroxyprogesterone acetate. Contraception. 2000;61:385–390.
- Wirth MM, Scherer SM, Hoks RM, et al. The effect of cortisol on emotional responses depends on order of cortisol and placebo administration in a within-subject design. Psychoneuroendocrinology. 2011;36:945–954.